Stocks and Investing Stocks and Investing
Wed, October 13, 2021
Tue, October 12, 2021

David Lebowitz Maintained (ALNY) at Buy with Increased Target to $242 on, Oct 12th, 2021


Published on 2024-10-27 18:08:19 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Increased Target from $234 to $242 on, Oct 12th, 2021.

David has made no other calls on ALNY in the last 4 months.



There are 6 other peers that have a rating on ALNY. Out of the 6 peers that are also analyzing ALNY, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Gary Nachman of "BMO Capital" Maintained at Hold with Increased Target to $196 on, Friday, August 27th, 2021
  • Edward Tenthoff of "Piper Sandler" Downgraded from Buy to Hold and Held Target at $181 on, Wednesday, August 4th, 2021


These are the ratings of the 4 analyists that currently disagree with David


  • Esther Rajavelu of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $215 on, Monday, October 4th, 2021
  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $250 on, Friday, August 13th, 2021
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $216 on, Wednesday, August 4th, 2021
  • David Lebovitz of "Morgan Stanley" Maintained at Buy with Increased Target to $234 on, Wednesday, August 4th, 2021

Contributing Sources